Literature DB >> 2449882

Neovascularization in central retinal vein occlusion: electroretinographic findings.

M A Johnson1, S Marcus, M J Elman, T J McPhee.   

Abstract

Electroretinograms (ERGs) were measured in 15 patients with central retinal vein occlusion (CRVO). Seven of the patients had neovascularization of the iris (NVI) at the time of testing, and two developed NVI within one month of testing; six did not have NVI or any other form of neovascularization (NV) and were no longer considered to be at risk for NV from their present occlusion. The ERGs were recorded as a function of the stimulus intensity and to a 30-Hz flickering stimulus. A Naka-Rushton-type function was fit to b-wave amplitudes, measured as a function of stimulus intensity, to evaluate changes in ERG amplitude and sensitivity. Compared with eyes in the no-NV group, eyes developing NVI had significantly reduced ERG sensitivity and amplitudes. The distributions of sensitivity values in these two groups did not overlap. All of the eyes with NV showed large a- and b-wave and 30-Hz implicit time delays, but only one eye had a b/a-wave amplitude ratio close to or less than 1. A comparison of ERG sensitivity, amplitude data, and flicker timing data with retinal fluorescein angiography in a two-alternative forced-choice analysis showed that ERG sensitivity and amplitude loss were better than retinal fluorescein angiography at discriminating eyes with CRVO and NVI from eyes with CRVO without NVI.

Entities:  

Mesh:

Year:  1988        PMID: 2449882     DOI: 10.1001/archopht.1988.01060130374025

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  32 in total

1.  The a- and b-wave latencies as a prognostic indicator of neovascularisation in central retinal vein occlusion.

Authors:  M Moschos; D Brouzas; M Moschou; G Theodossiadis
Journal:  Doc Ophthalmol       Date:  1999       Impact factor: 2.379

2.  Extraction and modelling of oscillatory potentials.

Authors:  Bang Viet Bui; James Andrew Armitage; Algis Jonas Vingrys
Journal:  Doc Ophthalmol       Date:  2002-01       Impact factor: 2.379

3.  Extraction and modeling of the Oscillatory Potential: signal conditioning to obtain minimally corrupted Oscillatory Potentials.

Authors:  Peter H Derr; Andrew U Meyer; Edward J Haupt; Mitchell G Brigell
Journal:  Doc Ophthalmol       Date:  2002-01       Impact factor: 2.379

4.  Wide field multifocal and standard full field electroretinographic features of hemi retinal vein occlusion.

Authors:  Fiona Mary Dolan; Stuart Parks; David Keating; Gordon Neale Dutton
Journal:  Doc Ophthalmol       Date:  2006-01       Impact factor: 2.379

5.  Systemic human CR2-targeted complement alternative pathway inhibitor ameliorates mouse laser-induced choroidal neovascularization.

Authors:  Bärbel Rohrer; Beth Coughlin; Mausumi Bandyopadhyay; V Michael Holers
Journal:  J Ocul Pharmacol Ther       Date:  2012-02-06       Impact factor: 2.671

6.  Empiric limits of rod photocurrent component underlying a-wave response in the electroretinogram.

Authors:  M E Breton; D P Montzka
Journal:  Doc Ophthalmol       Date:  1992       Impact factor: 2.379

7.  Hypobaric hypoxia reduces the amplitude of oscillatory potentials in the human ERG.

Authors:  Márta Janáky; Andor Grósz; Erika Tóth; Krisztina Benedek; György Benedek
Journal:  Doc Ophthalmol       Date:  2007-01-09       Impact factor: 2.379

8.  Dark-adapted luminance-response functions with skin and corneal electrodes.

Authors:  N Wali; L E Leguire
Journal:  Doc Ophthalmol       Date:  1991       Impact factor: 2.379

9.  The flicker electroretinogram interocular amplitude ratio is a strong prognostic indicator of neovascularization in patients with central retinal vein occlusion.

Authors:  Hsi-Kung Kuo; Ming-Tse Kuo; Yung-Jen Chen; Pei-Chang Wu; Chih-Hsin Chen; Yi-Hao Chen
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-10-08       Impact factor: 3.117

Review 10.  Central retinal vein occlusion: what's the story?

Authors:  T H Williamson
Journal:  Br J Ophthalmol       Date:  1997-08       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.